MindWalk Holdings Corp. (HYFT) Form 6-K — Oct 14, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) announced three senior scientific appointments to strengthen its Boston-based development leadership as its pipeline advances toward preclinical efficacy studies. The new hires are Zachary Maben, PhD, Director of Antigen Discovery & Protein Engineering, from Arbor Biotechnologies, and Joanne Lim, PhD, Director of Preclinical Development, from Orum Therapeutics; existing VP Shuji Sato expands his role to include the pipeline. All bring large-pharma and biotech experience from Pfizer, Novartis, Codiak, and Dragonfly.
Key figures
- Hyft patterns
- 660 million
- New appointments
- 3
- Hyft relationships
- 25 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.